Are You Eligible for the Use of Monoclonal Antibodies?
Eligibility for monoclonal antibody (mAb) treatment for COVID-19 is determined by specific criteria established by the Food and Drug Administration (FDA). The eligibility is based on factors such as age, underlying medical conditions, and the severity of the COVID-19 infection.
General eligibility criteria for monoclonal antibody treatment against COVID-19 may include:
1. Age: Patients must be 12 years of age or older.
2. High-Risk Conditions: Individuals with certain underlying medical conditions that increase their risk of severe illness from COVID-19 are eligible for mAb treatment. These conditions may include:
- Cardiovascular disease (including hypertension)
- Diabetes
- Chronic kidney disease
- Chronic lung disease
- Immunosuppression (including cancer, HIV/AIDS, or transplant recipients)
- Obesity (BMI ≥ 35 kg/m2)
- Other conditions determined by a healthcare provider
3. Symptom Duration: Patients must have mild or moderate symptoms of COVID-19 that have been present for less than 10 days.
4. Positive COVID-19 Test: Eligibility is restricted to individuals who have tested positive for COVID-19 using a molecular test (e.g., PCR test).
5. Hospitalization or Death: Monoclonal antibody treatment is not recommended for patients requiring hospitalization due to severe COVID-19 or those at high risk of progressing to severe illness.
It's important to note that the specific criteria may vary based on the type of monoclonal antibody being used. Additionally, the availability of mAb treatment can change depending on the supply, local guidelines, and healthcare provider's judgment.
If you believe you may be eligible for monoclonal antibody treatment for COVID-19, it is essential to consult with a healthcare provider promptly to determine your suitability and receive appropriate guidance. They can assess your individual situation, confirm eligibility, and provide the necessary care.